CuraTeQ Biologics Private Limited, a fully integrated arm of Aurobindo Pharma Ltd, has announced significant progress in its biosimilar program, revealing that its Omalizumab biosimilar candidate, BP11, has successfully met the primary endpoints in a Phase 1 trial. The study, engaging 165 healthy volunteers across Australia and New Zealand, was designed to compare BP11 with […]
Aurobindo Pharma has announced positive results from a Phase 3 clinical trial of its breast cancer biosimilar product, BP02 (Trastuzumab or biosimilar to Herceptin), developed by its subsidiary, Curateq Biologics. The clinical trial demonstrated that BP02 has a comparable efficacy and safety profile to Herceptin. The trial was a multi-center, randomized, double-blind study involving women […]
